ArticleTranslational oncology2026
Single-cell transcriptome analysis indicated that immune-related programmed cell death modification features could predict the clinical outcomes of patients with ovarian cancer.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvarian cancer (OV) is characterized by the highest mortality rate among gynecological malignancies. Suboptimal early diagnosis and ineffective prognostic prediction of OV contribute to poor survival outcomes for most patients. This study aimed to identify immune-related programmed cell death (IPCD) signatures and find the valuable biomarker for predicting OV prognosis.
methodsAll OV datasets were downloaded from public databases of TCGA, GEO and ICGC. Prognostic genes from IPCD-related differential genes were screened by univariate cox regression analysis. The construction of the IPCDS model was performed via 101 algorithm combinations. The prognostic performance of IPCDS model were examined by Kaplan-Meier analysis and timeROC curves. TIDE algorithm was used to predict the immune response of TCGA data.
results88 IPCD-related prognostic genes were screened for modeling IPCDS. A significantly higher OS in low-IPCDS group was observed among most OV datasets than in high-IPCDS group. 2-, 3-, and 5-year timeROC results of each OV dataset revealed the excellent predictive value of IPCDS for OV, showing a relatively higher AUC after treated 2 years. The low IPCDS group had a higher TIDE value, while the no response group had a higher IPCDS value. In the pan-cancer immunotherapy dataset, patients in the low IPCDS group had a longer overall survival period and a significant immunotherapy effect. Besides, model gene PDGFRA were found to have predictive performance for OV. We validated the upregulation of PDGFRA and C-MYC in ovarian cancer tissues through Western blot and confirmed their co-localization and immunofluorescence analyses.
conclusionOur study develops a novel prognostic model IPCDS for OV. IPCD-related gene PDGFRA serves as a prognosis factor play in predicting survival outcomes of OVs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.